Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer

Tingsong Yang¹, Xiaojun Shen¹, Xiaojun Tang², Guo Wei¹, Hao Zhang¹, Chenghui Du¹, Xuchao Xue¹, Liye Ma¹, Mingming Nie¹, and Jianwei Bi¹

¹Department of General Surgery, The First Affiliated Hospital, Second Military Medical University, Shanghai; ²Department of General Surgery, The First People's Hospital of Huai'an, Nanjing Medical University, Jiangsu Province, China

ABSTRACT

Aims and background. The efficacy of chemotherapy for advanced gastric cancer is now widely accepted. However, the survival advantage is small, and no internationally accepted standard regimen has emerged. The present study investigated the efficacy and safety of oxaliplatin plus oral capecitabine (XELOX regimen) as first-line chemotherapy in previously untreated patients with advanced gastric cancer.

Methods and study design. Patients received intravenous oxaliplatin (130 mg/m² over 2 h on day 1) plus oral capecitabine (1,000 mg/m² twice daily on days 1-14). Treatments were repeated every 3 weeks.

Results. Seventy-four patients were enrolled in the study, median age was 61 years (range, 32-74); median follow-up was 13.2 months (range, 2-24.5). In total, 364 cycles of chemotherapy were delivered. Overall response rate was 62.2% (95% CI, 51.2-73.2), with 3 complete and 43 partial responses; median time to progression and overall survival were 5.9 (95% CI, 4.8-7.0) and 10.8 months (95% CI, 7.9-13.7), respectively. The most common hematological adverse event was anemia (67.6% of patients). Grade 3-4 neutropenia was observed in 5 patients. The most common nonhematological toxicities were neuropathy (64.9%), nausea/vomiting (48.6%), diarrhea (28.4%), and hand-foot syndrome (39.2%). Grade 3-4 toxicities were rare. There were no treatment-related deaths.

Conclusions. The XELOX regimen was active and well-tolerated as first-line chemotherapy in patients with advanced gastric cancer.

Key words: advanced gastric cancer, capecitabine, oxaliplatin.

Correspondence to: Jianwei Bi, MD, PhD, Department of General Surgery, The First Affiliated Hospital, Second Military Medical University, 174 Changhui Road, Shanghai 200433, PR China. Tel +86-21-81873336; Fax +86-21-81873336; e-mail bijwei@yahoo.com.cn

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Received October 15, 2010; accepted March 4, 2011.